J. R. Corte

发表

Structure-activity relationships of anthranilamide-based factor Xa inhibitors containing piperidinone and pyridinone P4 moieties.

Chong-Hwan Chang, P. Lam, D. Cheney, 2008, Bioorganic & medicinal chemistry letters.

Structure-Based Design of Macrocyclic Factor XIa Inhibitors: Discovery of the Macrocyclic Amide Linker.

S. Sheriff, D. Seiffert, J. Bozarth, 2017, Journal of medicinal chemistry.

Pyridine and pyridinone-based factor XIa inhibitors.

P. Morin, D. Seiffert, A. Rendina, 2015, Bioorganic & medicinal chemistry letters.

Methyl-2,2-difluoro-2-(fluorosulfonyl) acetate (MDFA)/copper (I) iodide mediated and tetrabutylammonium iodide promoted trifluoromethylation of 1-aryl-4-iodo-1,2,3-triazoles

A. Mathur, Anuradha Gupta, R. Nimje, 2020 .

Discovery of novel 1-arylmethyl pyrrolidin-2-yl ethanol amines as calcium-sensing receptor antagonists.

J. Y. Roberge, Roy J. Vaz, R. Seethala, 2005, Bioorganic & medicinal chemistry letters.

Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy.

Michael A. Galella, S. Sheriff, A. Mathur, 2021, Journal of medicinal chemistry.

Discovery of a High Affinity, Orally Bioavailable Macrocyclic FXIa Inhibitor with Antithrombotic Activity in Preclinical Species.

P. Lam, S. Sheriff, A. Mathur, 2020, Journal of medicinal chemistry.

Macrocyclic inhibitors of Factor XIa: Discovery of alkyl-substituted macrocyclic amide linkers with improved potency.

P. Lam, S. Sheriff, D. Seiffert, 2017, Bioorganic & medicinal chemistry letters.

Novel phenylalanine derived diamides as Factor XIa inhibitors.

P. Lam, P. Morin, D. Seiffert, 2016, Bioorganic & medicinal chemistry letters.

Recurrent lacunar ischaemic stroke due to resistance to antiplatelet treatment: examining the need for personalised antithrombotic therapy.

S. Calleja, J. R. Corte, M. Delgado, 2015, Neurologia.

Phenylimidazoles as potent and selective inhibitors of coagulation factor XIa with in vivo antithrombotic activity.

A. Mathur, P. Morin, D. Seiffert, 2014, Journal of medicinal chemistry.

[Hereditary spherocytosis: clinical characteristics and treatment with splenectomy].

J. R. Corte, M. Vargas, A. Ramírez, 1995, Sangre.

Efficient synthesis of 2-aryl-6-chloronicotinamides via PXPd2-catalyzed regioselective Suzuki coupling.

Wu Yang, J. R. Corte, Yufeng Wang, 2003, Organic letters.

Synthesis and characterization of 3-arylquinazolinone and 3-arylquinazolinethione derivatives as selective estrogen receptor beta modulators.

Rong Zhou, Zhengping Ma, Terry Stouch, 2006, Journal of medicinal chemistry.

Orally bioavailable amine-linked macrocyclic inhibitors of factor XIa

P. Lam, S. Sheriff, D. Seiffert, 2020 .

Orally bioavailable amine-linked macrocyclic inhibitors of factor XIa.

P. Lam, S. Sheriff, D. Seiffert, 2020, Bioorganic & medicinal chemistry letters.

Potent, Orally Bioavailable and Efficacious Macrocyclic Inhibitors of Factor XIa. Discovery of Pyridine-Based Macrocycles Possessing Phenylazole Carboxamide P1 Groups.

P. Lam, S. Sheriff, A. Mathur, 2019, Journal of medicinal chemistry.

Orally bioavailable pyridine and pyrimidine-based Factor XIa inhibitors: Discovery of the methyl N-phenyl carbamate P2 prime group.

S. Sheriff, D. Seiffert, A. Rendina, 2016, Bioorganic & medicinal chemistry.

The dicobalt hexacarbonyl(alkyne) moiety as a stereocontrol element in intramolecular Friedel–Crafts alkylations1

N. Rath, J. R. Corte, R. Spencer, 1994 .

Characterization of a new class of selective nonsteroidal progesterone receptor agonists

J. Y. Roberge, D. Schnur, R. Seethala, 2004, Steroids.

Structure-based design of inhibitors of coagulation factor XIa with novel P1 moieties.

S. Sheriff, P. Morin, D. Seiffert, 2015, Bioorganic & medicinal chemistry letters.

Macrocyclic factor XIa inhibitors.

S. Sheriff, D. Seiffert, J. Bozarth, 2017, Bioorganic & medicinal chemistry letters.

Use of dicobalt hexacarbonyl-estabilized propargyl cations in intramolecular Friedel-Crafts alkylations

F. Miskevich, Chase C. Smith, J. R. Corte, 1990 .

Structure based design of macrocyclic factor XIa inhibitors: Discovery of cyclic P1 linker moieties with improved oral bioavailability.

David S Nirschl, P. Lam, S. Sheriff, 2019, Bioorganic & medicinal chemistry letters.